EGFR/HER2 mutant-selective inhibitor HS-10376

{
  "id": "MLC-T-ONC-013280",
  "term": "EGFR/HER2 mutant-selective inhibitor HS-10376",
  "field": "Oncology and biomedicine",
  "definition": "An orally bioavailable, mutant-selective, dual kinase inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), with potential antineoplastic activity. Upon oral administration, EGFR/HER2 mutant-selective inhibitor HS-10376 targets, binds to, and inhibits the activity of EGFR and HER2 with exon20 insertion mutations, thereby preventing EGFR- and HER2-mediated signaling. This may result in the inhibition of tumor growth and angiogenesis, and tumor regression in EGFR/HER2-expressing tumors. EGFR and HER2 are receptor tyrosine kinases that play major roles in tumor cell proliferation and tumor vascularization.",
  "synonyms": [
    "EGFR/HER2 exon 20 inhibitor HS-10376"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/egfr-her2-mutant-selective-inhibitor-hs-10376/"
}